详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer.

文献详情

资源类型：

收录情况： ◇ EI

作者：

机构： [a]Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, PR China [b]Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu, PR China [c]Department of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, USA [d]Southern Connecticut State University, New Haven, CT, United States [e]Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, United States [f]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China [g]Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, PR China [h]Department of Clinical Laboratory, Second Affiliated Hospital of Dalian Medical University, Dalian, China

出处：

DOI：

ISSN：

关键词： Colorectal cancer Immunotherapy Interleukin-12 Nanoparticles

摘要：

For the past few years, immunotherapy has recently shown considerable clinical benefit in CRC therapy, and the application of immunologic therapies in cancer treatments continues to increase perennially. Interleukin-12, an ideal candidate for tumor immunotherapy, could activate both innate and adaptive immunities. In this study, we developed a novel gene delivery system with a self-assembly method by MPEG-PLA and DOTAP(DMP) with zeta-potential value of 38.5mV and size of 37.5nm. The supernatant of lymphocytes treated with supernatant from Ct26 transfected pIL12 with DMP could inhibit Ct26 cells growth ex vivo. Treatment of tumor-bearing mice with DMP-pIL12 complex has significantly inhibited tumor growth at both the subcutaneous and peritoneal model in vivo by inhibiting angiogenesis, promoting apoptosis and reducing proliferation. The IL-12 plasmid and DMP complex may be used to treat the colorectal cancer in clinical as a new drug. Copyright © 2017 Elsevier Inc. All rights reserved.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

工程技术

小类 | 2 区医学：研究与实验 3 区纳米科技

最新[2023]版：

大类 | 2 区医学

小类 | 3 区医学：研究与实验 3 区纳米科技

第一作者：

第一作者机构： [a]Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, PR China

共同第一作者：

通讯作者：

通讯机构： [a]Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, PR China [*1]Department of Neurosurgery and Institute of Neurosurgery, Sichuan University, Chengdu, PR China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer.

文献详情

相关文献